Ask an Expert
AstraZeneca has announced a strategic investment of ₹176 crore to expand its Global Innovation & Technology Centre (GITC) in Chennai, marking its third major investment in India over the past two years. The funding will be used to enhance the centre’s infrastructure and capabilities, especially in advanced technology areas such as artificial intelligence, machine learning, data analytics, and data science.
These improvements are intended to support the development of next-generation medicines, digital healthcare solutions, and data-driven innovations that improve patient outcomes. Chennai has emerged as a key innovation hub for AstraZeneca’s global operations, and the company says this investment reflects its commitment to integrating cutting-edge technologies across its healthcare work. The expansion is also expected to generate skilled job opportunities, deepen collaboration with local talent, and strengthen Tamil Nadu’s position as a destination for global innovation and high-impact industries.
AstraZeneca’s presence in India includes technology, global business services, and research and development hubs, employing over 5,000 people nationwide. Tamil Nadu Chief Minister MK Stalin highlighted that the additional investment reinforces the state’s reputation as a centre of excellence in innovation and healthcare technology.
